Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses
ObjectivesThe use of bioprostheses in surgical aortic valve replacement (SAVR) has increased in younger patients. Comparative analysis of different types of bioprostheses is lacking. We aimed to compare two proprietary bioprostheses with different designs, i.e., internally and externally mounted lea...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.822893/full |
| _version_ | 1798015730756616192 |
|---|---|
| author | Rüdiger Lange Rüdiger Lange Rüdiger Lange Zahra Alalawi Zahra Alalawi Stephanie Voss Stephanie Voss Johannes Boehm Johannes Boehm Markus Krane Markus Krane Markus Krane Markus Krane Keti Vitanova Keti Vitanova |
| author_facet | Rüdiger Lange Rüdiger Lange Rüdiger Lange Zahra Alalawi Zahra Alalawi Stephanie Voss Stephanie Voss Johannes Boehm Johannes Boehm Markus Krane Markus Krane Markus Krane Markus Krane Keti Vitanova Keti Vitanova |
| author_sort | Rüdiger Lange |
| collection | DOAJ |
| description | ObjectivesThe use of bioprostheses in surgical aortic valve replacement (SAVR) has increased in younger patients. Comparative analysis of different types of bioprostheses is lacking. We aimed to compare two proprietary bioprostheses with different designs, i.e., internally and externally mounted leaflets, focusing on the long-term durability and survival.MethodsWe conducted a large single-center retrospective analysis of all consecutive patients who underwent SAVR with either Perimount™ or Trifecta™ bioprostheses between 2001 and 2019. The patient groups were further subdivided by age <65 and >65. Endpoints of the study were all-cause mortality and reoperation due to bioprosthetic valve failure (BVF).ResultsSelection criteria resulted in a total sample of 5,053 patients; 2,630 received a Perimount prosthesis (internally mounted leaflets) and 2,423 received a Trifecta prosthesis (externally mounted leaflets). The mean age at surgery was similar (69 ± 11 y, PM, and 68 ± 10 y, TF, p = 0.9), as was estimated survival at 8 years (76.1 ± 1.3%, PM, and 63.7 ± 1.9% TF; p=0.133). Patients in the Trifecta group had a significantly higher cumulative reoperation rate at 8 years compared to those in the Perimount group (16.9 ± 1.9% vs. 3.8 ± 0.4%; p < 0.01). This difference persisted across age groups (<65 y, 13.3% TF vs. 8.6% PM; >65 y, 12% TF vs. 7% PM).ConclusionBioprostheses for SAVR with externally mounted leaflets (Trifecta) showed significantly higher long-term reoperation rates compared to those with internally mounted leaflets (Perimount), regardless of the patient's age at SAVR. Survival was similar with both bioprostheses. |
| first_indexed | 2024-04-11T15:39:39Z |
| format | Article |
| id | doaj.art-c3f26195af444f53b805fc75e001ce75 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-11T15:39:39Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-c3f26195af444f53b805fc75e001ce752022-12-22T04:15:51ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-01-01810.3389/fcvm.2021.822893822893Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ BioprosthesesRüdiger Lange0Rüdiger Lange1Rüdiger Lange2Zahra Alalawi3Zahra Alalawi4Stephanie Voss5Stephanie Voss6Johannes Boehm7Johannes Boehm8Markus Krane9Markus Krane10Markus Krane11Markus Krane12Keti Vitanova13Keti Vitanova14Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyInsure (Institute of Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyDZHK (German Center for Cardiovascular Research)–Partner Site Munich Heart Alliance, Munich, GermanyDepartment of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyInsure (Institute of Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyDepartment of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyInsure (Institute of Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyDepartment of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyInsure (Institute of Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyDepartment of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyInsure (Institute of Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyDZHK (German Center for Cardiovascular Research)–Partner Site Munich Heart Alliance, Munich, GermanyDivision of Cardiac Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, United StatesDepartment of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyInsure (Institute of Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center Munich, Technische Universität München, Munich, GermanyObjectivesThe use of bioprostheses in surgical aortic valve replacement (SAVR) has increased in younger patients. Comparative analysis of different types of bioprostheses is lacking. We aimed to compare two proprietary bioprostheses with different designs, i.e., internally and externally mounted leaflets, focusing on the long-term durability and survival.MethodsWe conducted a large single-center retrospective analysis of all consecutive patients who underwent SAVR with either Perimount™ or Trifecta™ bioprostheses between 2001 and 2019. The patient groups were further subdivided by age <65 and >65. Endpoints of the study were all-cause mortality and reoperation due to bioprosthetic valve failure (BVF).ResultsSelection criteria resulted in a total sample of 5,053 patients; 2,630 received a Perimount prosthesis (internally mounted leaflets) and 2,423 received a Trifecta prosthesis (externally mounted leaflets). The mean age at surgery was similar (69 ± 11 y, PM, and 68 ± 10 y, TF, p = 0.9), as was estimated survival at 8 years (76.1 ± 1.3%, PM, and 63.7 ± 1.9% TF; p=0.133). Patients in the Trifecta group had a significantly higher cumulative reoperation rate at 8 years compared to those in the Perimount group (16.9 ± 1.9% vs. 3.8 ± 0.4%; p < 0.01). This difference persisted across age groups (<65 y, 13.3% TF vs. 8.6% PM; >65 y, 12% TF vs. 7% PM).ConclusionBioprostheses for SAVR with externally mounted leaflets (Trifecta) showed significantly higher long-term reoperation rates compared to those with internally mounted leaflets (Perimount), regardless of the patient's age at SAVR. Survival was similar with both bioprostheses.https://www.frontiersin.org/articles/10.3389/fcvm.2021.822893/fullBVFSAVR-surgical aortic valve replacementbioprosthesesbioprosthesis adverse effectsbioprosthesis avr |
| spellingShingle | Rüdiger Lange Rüdiger Lange Rüdiger Lange Zahra Alalawi Zahra Alalawi Stephanie Voss Stephanie Voss Johannes Boehm Johannes Boehm Markus Krane Markus Krane Markus Krane Markus Krane Keti Vitanova Keti Vitanova Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses Frontiers in Cardiovascular Medicine BVF SAVR-surgical aortic valve replacement bioprostheses bioprosthesis adverse effects bioprosthesis avr |
| title | Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses |
| title_full | Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses |
| title_fullStr | Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses |
| title_full_unstemmed | Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses |
| title_short | Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses |
| title_sort | different rates of bioprosthetic aortic valve failure with perimount™ and trifecta™ bioprostheses |
| topic | BVF SAVR-surgical aortic valve replacement bioprostheses bioprosthesis adverse effects bioprosthesis avr |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.822893/full |
| work_keys_str_mv | AT rudigerlange differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT rudigerlange differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT rudigerlange differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT zahraalalawi differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT zahraalalawi differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT stephanievoss differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT stephanievoss differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT johannesboehm differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT johannesboehm differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT markuskrane differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT markuskrane differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT markuskrane differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT markuskrane differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT ketivitanova differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses AT ketivitanova differentratesofbioprostheticaorticvalvefailurewithperimountandtrifectabioprostheses |